Literature DB >> 1638031

Dynamic assessment of quality of life after autologous bone marrow transplantation.

N J Chao1, D K Tierney, J R Bloom, G D Long, T A Barr, B A Stallbaum, R M Wong, R S Negrin, S J Horning, K G Blume.   

Abstract

To determine the quality of life in adult patients after autologous bone marrow transplantation (BMT), we administered a questionnaire to a cohort of patients seen at a single referral-based center. The sample included adults 18 years and older during the 1 year following an autologous BMT. Both disease-free patients and those who relapsed with 1-year of follow-up data available were included. Of 59 eligible patients, 58 (98%) responded to the questionnaire. Patients completed a telephone questionnaire administered by a nurse specialist in the field of BMT approximately every 90 days. At the time of initial contact on day +90, the mean quality of life was 7.8 (range, 1 to 10) on a scale of 1 to 10, with 10 being the best. By the end of the first year of follow-up, the mean quality of life was 8.9 (range, 3 to 10). Seventy-eight percent of the patients were employed. Twenty-one percent lost weight during the first year, with the majority reporting voluntary weight loss. Fourteen percent reported difficulties with sexual activity. Only 5% reported difficulty with sleeping or with frequent colds. One patient felt that her appearance was worse, and none of the patients reported a poor appetite. Eighty-eight percent of surviving adult patients reported an above-average to excellent quality of life 1 year following autologous BMT. This outcome is encouraging and suggests that this procedure is not associated with long-term morbidity in the surviving adult patient.

Entities:  

Mesh:

Year:  1992        PMID: 1638031

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

Review 1.  Hematopoietic stem cell transplantation: a primer for the primary care physician.

Authors:  Chantal S Léger; Thomas J Nevill
Journal:  CMAJ       Date:  2004-05-11       Impact factor: 8.262

2.  Prognostic significance of pre-transplant quality of life in allogeneic hematopoietic cell transplantation recipients.

Authors:  B K Hamilton; A D Law; L Rybicki; D Abounader; J Dabney; R Dean; H K Duong; A T Gerds; R Hanna; B T Hill; D Jagadeesh; M E Kalaycio; C Lawrence; L McLellan; B Pohlman; R M Sobecks; B J Bolwell; N S Majhail
Journal:  Bone Marrow Transplant       Date:  2015-06-01       Impact factor: 5.483

Review 3.  Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF): an appraisal of its pharmacoeconomic status in neutropenia associated with chemotherapy and autologous bone marrow transplant.

Authors:  K L Goa; H M Bryson
Journal:  Pharmacoeconomics       Date:  1994-01       Impact factor: 4.981

4.  The impact of paediatric bone marrow transplantation on quality of life.

Authors:  L Nespoli; A P Verri; F Locatelli; L Bertuggia; R M Taibi; G R Burgio
Journal:  Qual Life Res       Date:  1995-06       Impact factor: 4.147

Review 5.  Sexuality in patients undergoing haematopoietic stem cell transplantation.

Authors:  Sarah Jayne Liptrott; Emad Shash; Giovanni Martinelli
Journal:  Int J Hematol       Date:  2011-11-15       Impact factor: 2.490

6.  High-dose chemotherapy with autologous stem cell rescue in breast cancer.

Authors:  R O Dillman; N M Barth; S K Nayak; C DeLeon; A O'Connor; L Morrelli
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

Review 7.  Health-related quality of life following haematopoietic cell transplantation: patient education, evaluation and intervention.

Authors:  Joseph Pidala; Claudio Anasetti; Heather Jim
Journal:  Br J Haematol       Date:  2009-11-16       Impact factor: 6.998

8.  Design of the EXercise Intervention after Stem cell Transplantation (EXIST) study: a randomized controlled trial to evaluate the effectiveness and cost-effectiveness of an individualized high intensity physical exercise program on fitness and fatigue in patients with multiple myeloma or (non-) Hodgkin's lymphoma treated with high dose chemotherapy and autologous stem cell transplantation.

Authors:  Saskia Persoon; Marie José Kersten; Mai J M Chinapaw; Laurien M Buffart; Heleen Burghout; Goof Schep; Johannes Brug; Frans Nollet
Journal:  BMC Cancer       Date:  2010-12-06       Impact factor: 4.430

9.  Single high-dose etoposide and melphalan with non-cryopreserved autologous marrow rescue as primary therapy for relapsed, refractory and poor-prognosis Hodgkin's disease.

Authors:  L K Seymour; R D Dansey; W R Bezwoda
Journal:  Br J Cancer       Date:  1994-09       Impact factor: 7.640

10.  Quality of life following bone marrow transplantation: findings from a multicentre study.

Authors:  M A Andrykowski; C B Greiner; E M Altmaier; T G Burish; J H Antin; R Gingrich; C McGarigle; P J Henslee-Downey
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.